Ceritinib has demonstrated antitumor activity in hepatocellular carcinoma cells by inhibiting the ALK and insulin-like growth factor 1 receptor (IGF1R) signaling pathways [20]. This evidence concerns the gene IGF1R and hepatocellular carcinoma.